Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERACT-ION
2024-514083-31-00Phase 2Authorised
- Sponsor
- CHRU Nancy
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ezabenlimab in anal squamous cell carcinoma (SCCA), sponsored by CHRU Nancy. Primary endpoint: Clinical complete response (cCR). Planned start Jul 2024; status: authorised.
02
Drugs
ezabenlimab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2024-514083-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514083-31-00.